Uncategorized

Genascence to Present Full Data from Phase 1 Clinical Trial on GNSC-001, Company’s Lead Program in Osteoarthritis, at European Society of Gene & Cell Therapy 30th Annual Congress

Genascence Corporation announced that data from the Phase 1 clinical trial of GNSC-001 for the treatment of osteoarthritis demonstrated that it was safe and well tolerated.

Genascence to Present Full Data from Phase 1 Clinical Trial on GNSC-001, Company’s Lead Program in Osteoarthritis, at European Society of Gene & Cell Therapy 30th Annual Congress Read More »

Recbio appeared at the 14th China (Taizhou) International Pharmaceutical Fair

From October 19 to 22, the 14th China International Pharmaceutical Fair, sponsored by the China Chamber of International Commerce and hosted by the Taizhou Municipal People’s Government and Jiangsu Branch of the China Council for the Promotion of International Trade, was successfully held in Taizhou China Pharmaceutical City.

Recbio appeared at the 14th China (Taizhou) International Pharmaceutical Fair Read More »

Scroll to Top